Literature DB >> 11820909

Case-population studies in pharmacoepidemiology.

Dolors Capellà1, Consuelo Pedrós, Xavier Vidal, Joan-Ramon Laporte.   

Abstract

The case-population approach aims at providing a risk estimate by comparing the incidence of the disease of interest among those exposed to the drug under study with the incidence among the non-exposed. For that purpose, the cases with the disease of interest have to be ascertained independently of the exposure status. Their rate and pattern of exposure have to be ascertained by interview with a structured questionnaire. Information on the patterns and the prevalence of drug consumption is needed in order to estimate the rate of exposure, and drug consumption statistics can be used to this end. In this paper, we review the main characteristics of studies using this approach or a similar one, and studies where series of cases exposed to the drug of interest were compared with drug consumption statistics. We looked at selected basic methodological requirements. Most of the studies reviewed suffer from incomplete case ascertainment, inaccurate definition of the disease of interest, incomplete information on exposures and other risk factors, and/or limited control of potential confounding, among other limitations. All the reviewed studies had several limitations regarding the estimation of the population at risk. The methods used in case-population studies should be clearly described, particularly with respect to the identification of the cases (numerator) and the estimation of the consumption prevalence (denominator). Case-population studies can give approximate risk estimates, but the method should be validated by comparing its results with those of case-control studies.

Mesh:

Substances:

Year:  2002        PMID: 11820909     DOI: 10.2165/00002018-200225010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  42 in total

1.  FATAL APLASTIC ANEMIA. AN EPIDEMIOLOGICAL STUDY OF ITS RELATIONSHIP TO THE DRUG CHLORAMPHENICOL.

Authors:  K M SMICK; P K CONDIT; R L PROCTOR; V SUTCHER
Journal:  J Chronic Dis       Date:  1964-10

2.  Under-reporting of adverse drug reactions in general practice.

Authors:  Y Moride; F Haramburu; A A Requejo; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

3.  Agranulocytosis induced by cinepazide.

Authors:  J R Laporte; D Capellà; J Juan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Statewide study of chloramphenicol therapy and fatal aplastic anemia.

Authors:  R O Wallerstein; P K Condit; C K Kasper; J W Brown; F R Morrison
Journal:  JAMA       Date:  1969-06-16       Impact factor: 56.272

5.  Drug use in pregnancy: a comparative appraisal of data collecting methods.

Authors:  L T de Jong-van den Berg; C M Waardenburg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Epidemiology of adverse drug reactions to phenformin and metformin.

Authors:  U Bergman; G Boman; B E Wiholm
Journal:  Br Med J       Date:  1978-08-12

7.  Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence.

Authors:  M Keisu; E Ekman
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.

Authors:  P Hörnsten; M Keisu; B E Wiholm
Journal:  Arch Dermatol       Date:  1990-07

9.  A population based case-cohort study of drug-induced anaphylaxis.

Authors:  M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

10.  Extrapyramidal reactions with metoclopramide.

Authors:  D N Bateman; M D Rawlins; J M Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-05
View more
  9 in total

1.  The case-population study design: an analysis of its application in pharmacovigilance.

Authors:  Hélène Théophile; Joan-Ramon Laporte; Nicholas Moore; Karin-Latry Martin; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

2.  On Designs for Vaccine Surveillance.

Authors:  Robert W Platt
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

3.  Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.

Authors:  Luis Hermenegildo Martin Arias; Antonio Martin Gonzalez; Rosario Sanz Fadrique; Esther Salgueiro; Maria Sainz
Journal:  Int J Clin Pharm       Date:  2018-07-31

4.  Sources of European drug consumption data at a country level.

Authors:  Pili Ferrer; Elena Ballarín; Mònica Sabaté; Joan-Ramon Laporte; Marieke Schoonen; Marietta Rottenkolber; Joan Fortuny; Joerg Hasford; Iain Tatt; Luisa Ibáñez
Journal:  Int J Public Health       Date:  2014-05-30       Impact factor: 3.380

5.  Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Authors:  Hélène Théophile; Nicholas Moore; Philip Robinson; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

6.  Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?

Authors:  Kristian Svendsen; Kjell H Halvorsen; Solveig Vorren; Hilde Samdal; Beate Garcia
Journal:  Eur J Clin Pharmacol       Date:  2017-12-18       Impact factor: 2.953

7.  Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.

Authors:  Linda de Jonge; Priscilla A Zetstra-van der Woude; H Jens Bos; Lolkje T W de Jong-van den Berg; Marian K Bakker
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

8.  A surveillance method for the early identification of idiosyncratic adverse drug reactions.

Authors:  Fatma A Etwel; Michael J Rieder; John R Bend; Gideon Koren
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Authors:  Nicholas Moore; Stéphanie Duret; Adeline Grolleau; Régis Lassalle; Vanessa Barbet; Mai Duong; Nicolas Thurin; Cécile Droz-Perroteau; Sinem Ezgi Gulmez
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.